F-star Therapeutics, Inc. FSTX
Set alert
7.12 +7.12 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 156.51M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.07
- Beta
- -0.35
- Short ratio
- 2.59
- Inst. own
- 44.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 13, 2023
- 50-d avg
- 5.63
- 200-d avg
- 5.74
- 1y target
- 7.00
Analyst view
Consensus: hold
Hold
Price target (mean) 7.00
Recommendation trend
- 1 month ago 4
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.39 | -0.46 – -0.32 | 0.48 | -181.2% | 0 | 0.0% | 2 |
| Next quarter | -0.76 | -0.76 – -0.76 | -0.57 | -33.3% | 0 | 0.0% | 1 |
| Current year | -2.47 | -2.61 – -2.33 | -1.88 | -31.4% | 4.34M | -79.5% | 2 |
| Next year | -3.44 | -4.66 – -2.23 | -2.47 | -39.3% | 2.50M | -42.4% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 15, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jun 24, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| May 11, 2022 | SVB Leerink | Maintained | — | Outperform |
| Mar 17, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 17, 2021 | SVB Leerink | Maintained | — | Outperform |
| Jul 8, 2021 | SVB Leerink | Initiated | — | Outperform |
| Jun 9, 2021 | B. Riley Securities | Initiated | — | Buy |
| May 18, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Apr 16, 2021 | Oppenheimer | Initiated | — | Outperform |
| Apr 8, 2021 | William Blair | Initiated | — | Outperform |
| Mar 24, 2021 | Laidlaw & Co. | Initiated | — | Buy |
| Mar 1, 2021 | HC Wainwright & Co. | Initiated | — | Buy |